Guggenheim raises First Tracks stock price target to $110 on celiac data
Guggenheim raised its price target for First Tracks Biotherapeutics (TRAX) to $110 from $100, citing positive Phase Ib trial results for ANB033 in celiac disease. The stock trades at $46.34 with a $1.95B market cap, though some analysts suggest it may be overvalued. The company plans further studies and presentations, with additional analyst upgrades also reported.
How this was made
The 30-second read
Why it matters
Analyst upgrades and new Phase Ib data provide fresh catalyst for the stock.
Market read
The article introduces new clinical data and a price target increase, offering a fresh trading catalyst for TRAX.
What to watch
Potential dilution from recent capital raise and the need for Phase II data in 2027.
Background
First Tracks Biotherapeutics (TRAX) is a clinical‑stage biotech developing the anti‑CD122 antibody ANB033.
Ticker impact
Guggenheim raised its price target to $110 after First Tracks reported positive Phase Ib celiac disease trial results for ANB033.
likely upward pressure as investors price in increased success probability.
Analyst upgrade and fresh clinical data are new material that can move the share price immediately.
Market effects
Positive biotech trial results may lift sentiment across early‑stage biotech peers.
Limited to U.S. biotech sector.
Modest; primarily affects investors focused on clinical‑stage biotech.
Counterpoint
If the trial data does not translate into later‑stage success, the price target may be premature.
Key entities
- analystGuggenheim
Raised price target to $110 and maintained Buy rating.
- companyFirst Tracks Biotherapeutics
Reported positive Phase Ib results for ANB033 in celiac disease.
